In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report). The company’s shares closed yesterday at $14.83.
Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and Ascendis Pharma. According to TipRanks, Schwartz has an average return of 1.5% and a 42.83% success rate on recommended stocks.
Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $19.00.
See today’s best-performing stocks on TipRanks >>
Based on KalVista Pharmaceuticals’ latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $27.65 million. In comparison, last year the company had a GAAP net loss of $22.26 million
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals (KALV) Company Description:
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
Read More on KALV:
